Literature DB >> 30232540

The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals.

Francesco Ceci1,2, Giulia Polverari3,4, Jeremie Calais3, Paolo Castellucci4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30232540     DOI： 10.1007/s00259-018-4162-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  15 in total

Review 1.  PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.

Authors:  T Nelius; S Filleur
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

2.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Authors:  Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

Review 3.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

4.  Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Authors:  Peter Hoskin; Oliver Sartor; Joe M O'Sullivan; Dag Clement Johannessen; Svein I Helle; John Logue; David Bottomley; Sten Nilsson; Nicholas J Vogelzang; Fang Fang; Mona Wahba; Anne-Kirsti Aksnes; Christopher Parker
Journal:  Lancet Oncol       Date:  2014-10-17       Impact factor: 41.316

5.  Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer.

Authors:  Angelo Castello; H A Macapinlac; E Lopci; E B Santos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-21       Impact factor: 9.236

6.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Authors:  Joshua J Morigi; Phillip D Stricker; Pim J van Leeuwen; Reuben Tang; Bao Ho; Quoc Nguyen; George Hruby; Gerald Fogarty; Raj Jagavkar; Andrew Kneebone; Adam Hickey; Stefano Fanti; Lisa Tarlinton; Louise Emmett
Journal:  J Nucl Med       Date:  2015-06-25       Impact factor: 10.057

7.  PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.

Authors:  Salvatore L Burgio; Vincenza Conteduca; Britt Rudnas; Francesco Carrozza; Enrico Campadelli; Emanuela Bianchi; Paolo Fabbri; Marco Montanari; Elisa Carretta; Cecilia Menna; Ugo De Giorgi
Journal:  Clin Genitourin Cancer       Date:  2014-06-12       Impact factor: 2.872

8.  Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Ken-Ichiro Shiga; Hirofumi Koga; Akito Yamaguchi; Seiji Naito; Masatoshi Eto
Journal:  BJU Int       Date:  2016-04-06       Impact factor: 5.588

9.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

10.  Visceral disease in castration-resistant prostate cancer.

Authors:  C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.